Neurocrine Biosciences (NBIX) Other Non-Current Assets (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Other Non-Current Assets of $59.3 million for Q2 2026, up 174.54% year-over-year from $21.6 million in Q2 2025, and down 19.43% on a QoQ basis from $73.6 million in Q1 2026.
Neurocrine Biosciences (NBIX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Other Non-Current Assets for 17 years, with the latest figure at $59.3 million in Q2 2026.
- Other Non-Current Assets for Q2 2026 came in at $59.3 million, up 174.54% year-over-year; the trailing twelve-month figure through Jun 2026 was $59.3 million (up 174.54% YoY), and the FY2025 annual result was $48.7 million, down 6.35% from the prior year.
- Other Non-Current Assets fell to $59.3 million in Q2 2026, from $73.6 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $73.6 million in Q1 2026 and troughed at $10.0 million in Q2 2022.
- A 5-year average of $37.2 million and a median of $39.5 million in 2023 frame the typical range for Other Non-Current Assets.
- The widest annual swing landed in 2022, when Other Non-Current Assets soared 468.18%; it then tumbled 69.94% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $25.0 million in 2022, then jumped by 98.4% to $49.6 million in 2023, then climbed by 4.84% to $52.0 million in 2024, then dropped by 6.35% to $48.7 million in 2025, then grew by 21.77% to $59.3 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $59.3 million in Q2 2026, $73.6 million in Q1 2026, and $48.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.30 Mn |
| Mar 31, 2026 | 73.60 Mn |
| Dec 31, 2025 | 59.50 Mn |
| Sep 30, 2025 | 20.30 Mn |
| Jun 30, 2025 | 21.60 Mn |
| Mar 31, 2025 | 15.30 Mn |
| Dec 31, 2024 | 52.00 Mn |
| Sep 30, 2024 | 61.60 Mn |
| Jun 30, 2024 | 57.80 Mn |
| Mar 31, 2024 | 50.90 Mn |
| Dec 31, 2023 | 49.60 Mn |
| Sep 30, 2023 | 43.10 Mn |
| Jun 30, 2023 | 35.90 Mn |
| Mar 31, 2023 | 24.90 Mn |
| Dec 31, 2022 | 25.00 Mn |
| Sep 30, 2022 | 10.50 Mn |
| Jun 30, 2022 | 10.00 Mn |
| Mar 31, 2022 | 10.10 Mn |
| Dec 31, 2021 | 4.40 Mn |
| Sep 30, 2021 | 3.20 Mn |